J Clin Pathol. 2014 Jul 4. pii: jclinpath-2014-202467. doi: 10.1136/jclinpath-2014-202467. [Epub ahead of print]
RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
Wong NA1, Gonzalez D2, Salto-Tellez M3, Butler R4, Diaz-Cano SJ5, Ilyas M6, Newman W7, Shaw E8, Taniere P9, Walsh SV10.
Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
COLORECTAL CANCER; GENETICS; LABORATORY MANAGEMENT
- [PubMed - as supplied by publisher]